Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Idecabtagene vicleucel for R/R myeloma

Jesús San Miguel • 22 Jun 2020
EHA 2020
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Jesus San Miguel, MD, of the University of Navarra, Navarra, Spain, updates us on the KarMMa study (NCT03361748), which investigated the BCMA-targeted CAR-T cell therapy, idecabtagene vicleucel, in relapsed or refractory (R/R) multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús San Miguel

Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023
1:11
The future of myeloma therapy and where the treatment landscape is moving
Jesús San Miguel • 13 May 2022
1:21
The value of sustained MRD negativity in MM
Jesús San Miguel • 13 May 2022
1:21
MRD evaluation: how, when and for which goal?
Jesús San Miguel • 13 May 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals